HCP Live

Optimizing Anti-VEGF Treatment Outcomes in Neovascular AMD and DME : Episode 8

Current Treatment Options for nAMD

Jul 6, 2023

Ehsan Rahimy, MD
Jonathan Jonisch, MD

EP: 1.Overview of Anti-VEGF Treatments for AMD and DME

EP: 2.Barriers to Optimal Treatment Outcomes

EP: 3.Patient and Cross-Care Education Strategies for AMD and DME

EP: 4.Real-World Long-Term Safety Data of Anti-VEGF Agents

EP: 5.Treat and Extend Strategy for Anti-VEGF Injections

EP: 6.Markers of Disease Progression in nAMD Patients

EP: 7.Significance of SRF vs IRF in nAMD

EP: 8.Current Treatment Options for nAMD

Related Videos

Experts on AMD and DME.

Experts on AMD and DME.

Experts on AMD and DME.

Expert on AMD and DME.

Experts on AMD and DME.

Experts discuss AMD.

Experts on AMD.

Related Content

6 FDA Decisions Expected Before 2024

New Insight: The Journey to a Drug Approval with Cedric Francois, MD, PhD

Diabetic Microvascular Disease Associated with Left Ventricular Hypertrophy in T2D

New Insight: Making Waves in the Biotech Space with Jay Duker, MD

Prevalence of Diabetic Retinopathy Lower at Younger Age in Youth with T2D

Hypertension May Worsen the Risk of Diabetic Retinopathy Among Patients with T2D

6 FDA Decisions Expected Before 2024

New Insight: The Journey to a Drug Approval with Cedric Francois, MD, PhD

Diabetic Microvascular Disease Associated with Left Ventricular Hypertrophy in T2D

New Insight: Making Waves in the Biotech Space with Jay Duker, MD

Prevalence of Diabetic Retinopathy Lower at Younger Age in Youth with T2D

Hypertension May Worsen the Risk of Diabetic Retinopathy Among Patients with T2D

6 FDA Decisions Expected Before 2024

New Insight: The Journey to a Drug Approval with Cedric Francois, MD, PhD

Diabetic Microvascular Disease Associated with Left Ventricular Hypertrophy in T2D

New Insight: Making Waves in the Biotech Space with Jay Duker, MD

Prevalence of Diabetic Retinopathy Lower at Younger Age in Youth with T2D

Hypertension May Worsen the Risk of Diabetic Retinopathy Among Patients with T2D

Related Content

6 FDA Decisions Expected Before 2024

6 FDA Decisions Expected Before 2024

New Insight: The Journey to a Drug Approval with Cedric Francois, MD, PhD

New Insight: The Journey to a Drug Approval with Cedric Francois, MD, PhD

Diabetic Microvascular Disease Associated with Left Ventricular Hypertrophy in T2D

Diabetic Microvascular Disease Associated with Left Ventricular Hypertrophy in T2D

New Insight: Making Waves in the Biotech Space with Jay Duker, MD

New Insight: Making Waves in the Biotech Space with Jay Duker, MD

Prevalence of Diabetic Retinopathy Lower at Younger Age in Youth with T2D

Prevalence of Diabetic Retinopathy Lower at Younger Age in Youth with T2D

Hypertension May Worsen the Risk of Diabetic Retinopathy Among Patients with T2D

Hypertension May Worsen the Risk of Diabetic Retinopathy Among Patients with T2D

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.